The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

The Biden administration unveiled its list of 15 drugs, which include GLP-1 drugs Ozempic, Wegovy and Rybelsus, for the ...

The nature of the beast is yes, these drugs come off patent; the demand is there and someone could produce it more cheaply’, ...

There are many possible explanations for that, including side effects and the drug’s cost. According to a KFF analysis, the list price for GLP-1 drugs can range between $936 and $1,349 before ...

Safety Concerns and Liability Issues for GLP-1 Drugs GLP-1 medications ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly) increased ...

I recently learned of Eli Lilly & Co.’s (“Lilly”) recent lawsuit against FDA from Nicole DeFeudis, who interviewed me for her ...

the evolution of the markets in which Allurion competes and the rise of GLP-1 drugs, (iv) the ability of Allurion to defend its intellectual property and satisfy regulatory requirements ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

GLP-1 drugs, or GLP-1 receptor agonists ... has not added Saxenda to its essential medicines list. Exenatide, like semaglutide, increases the amount of GLP-1 hormones produced by the body. These ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to ... deliver data around the middle of 2025. Metsera’s to-do list includes the initiation of additional trials of MET-097i ...